{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T20:30:20Z","timestamp":1770928220937,"version":"3.50.1"},"reference-count":46,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2019,2,11]]},"DOI":"10.1080\/14656566.2018.1559299","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T13:33:30Z","timestamp":1545831210000},"page":"269-276","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents"],"prefix":"10.1080","volume":"20","author":[{"given":"Vania","family":"Giacomet","sequence":"first","affiliation":[{"name":",","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Cossu","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo F.","family":"Capetti","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GianVincenzo","family":"Zuccotti","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5183-7818","authenticated-orcid":false,"given":"Giuliano","family":"Rizzardini","sequence":"additional","affiliation":[{"name":",","place":["Italy"]},{"name":",","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,12,26]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"UNAIDS Data. 2017 [cited 2018 Aug 03]. Available from: http:\/\/www.unaids.org\/en\/resources\/documents\/2017\/2017_data_book"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/515596"},{"key":"e_1_3_3_5_1","unstructured":"Panel on antiretroviral therapy and medical management of children living with HIV guidelines for the use of antiretroviral agents in pediatric HIV infection. 2018 Oct 25. Available from: http:\/\/aidsinfo.nih.gov\/con-tentfiles\/lvguidelines\/pediatricguidelines.pdf"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2011.12.013"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20940"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800971"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5453.646"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit696"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.00000000000000848"},{"key":"e_1_3_3_12_1","unstructured":"Gilead Sciences Inc. E\/C\/F\/TAF_ (elvitegravir cobicistat emtricitabine and tenofovir alafenamide) tablets for oral use: US prescribing information. 2015 [cited 2018 Aug 03]. Availabel from: http:\/\/www.fda.gov"},{"key":"e_1_3_3_13_1","unstructured":"Gilead Sciences International Ltd. E\/C\/F\/TAF 150 mg\/150 mg\/200 mg\/10 mg film-coated tablets: EU summary of product characteristics. 2015 [cited 2018 Aug 03]. Availabel from: http:\/\/www.ema.europa.eu"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30121-7"},{"key":"e_1_3_3_17_1","unstructured":"Gilead Sciences Inc. E\/C\/F\/TAF (elvitegravir cobicistat emtricitabine and tenofovir alafenamide) tablets for oral use: US prescribing information. 2015 [cited 2018 Aug 23]. Availabel from: http:\/\/www.fda.gov"},{"key":"e_1_3_3_18_1","unstructured":"Gilead Sciences International Ltd. E\/C\/F\/TAF 150 mg\/150 mg\/200 mg\/10 mg film-coated tablets: EU summary of product characteristics. 2015 [cited 2018 Aug 23]. Availabel from: http:\/\/www.ema.europa.eu"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw765"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000908"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001186"},{"issue":"4","key":"e_1_3_3_22_1","first-page":"184","article-title":"Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys?","volume":"18","author":"Aloy B","year":"2016","unstructured":"Aloy B, Tazi I, Bagnis CI, et al. Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys? AIDS Rev. 2016 Oct-Dec;18(4):184\u2013192. [PubMed 27438578].","journal-title":"AIDS Rev"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.05.013"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.12.008"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00470-08"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02568-12"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0420-7"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01151-15"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.12.45"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2016.1142731"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2018.03.012"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30121-7"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31827b55f1"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky203"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31829e6b9f"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/v10020060"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002432"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001553"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001569"},{"key":"e_1_3_3_40_1","unstructured":"Custodio JM Liu Y Graham H et al. Bioequivalence of two pediatric formulations versus adult tablets formulations of elvitegravir (abstract n 902). 21st Conference on Retroviruses and Opportunist Infections; 2014 Mar 3\u20136; Boston."},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30121-7"},{"key":"e_1_3_3_42_1","unstructured":"Custodio JM Musiime V Gaur A et al. Pharmacokinetics and preliminary safety of elvitegravir in HIV-1 infected pediatric subjects [abstract n 951]. 21st Conference on Retroviruses and Opportunist Infections; 2014 Mar 3\u20136; Boston."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(17)30009-3"},{"key":"e_1_3_3_44_1","unstructured":"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. [cited 2018 Aug 07]. Availabel from: https:\/\/aidsinfo.nih.gov\/guidelines\/html\/2\/pediatric-arv\/0"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0024-z"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.844685"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S88490"},{"key":"e_1_3_3_48_1","article-title":"Pharmacokinetics, safety and efficacy of eviltegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide\/E\/C\/F\/TAF)single tablet regimen (STR)in HIV-1 infected antiretroviral treatment na\u00efve adolescents and virologically suppressed children","author":"Gilead Science","unstructured":"Gilead Science. Pharmacokinetics, safety and efficacy of eviltegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide\/E\/C\/F\/TAF)single tablet regimen (STR)in HIV-1 infected antiretroviral treatment na\u00efve adolescents and virologically suppressed children. ClinicalTrial. gov identifier NCT01854775. US National Insitute of Health. ClinicalTrials.gov. cited 2018 Aug 04. Availabel from: https:\/7clinicaltrials.gov","journal-title":"ClinicalTrial"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2018.1559299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T19:42:20Z","timestamp":1770925340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2018.1559299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,26]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2,11]]}},"alternative-id":["10.1080\/14656566.2018.1559299"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2018.1559299","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}